Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 35 | 2025 | 369 | 7.700 |
Why?
|
| Depressive Disorder, Major | 9 | 2025 | 453 | 1.480 |
Why?
|
| Antipsychotic Agents | 8 | 2024 | 381 | 1.350 |
Why?
|
| Temperament | 3 | 2025 | 32 | 1.170 |
Why?
|
| Suicide | 5 | 2024 | 203 | 1.120 |
Why?
|
| Depressive Disorder | 4 | 2019 | 481 | 1.070 |
Why?
|
| Suicidal Ideation | 6 | 2025 | 254 | 0.960 |
Why?
|
| Lithium Compounds | 3 | 2020 | 16 | 0.940 |
Why?
|
| Antimanic Agents | 5 | 2023 | 37 | 0.880 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 45 | 0.860 |
Why?
|
| Emotions | 4 | 2023 | 367 | 0.840 |
Why?
|
| Hippocampus | 6 | 2019 | 815 | 0.760 |
Why?
|
| Facial Expression | 1 | 2019 | 28 | 0.600 |
Why?
|
| Attention | 2 | 2020 | 200 | 0.580 |
Why?
|
| Anxiety | 4 | 2024 | 1001 | 0.570 |
Why?
|
| Depression | 7 | 2025 | 1350 | 0.550 |
Why?
|
| Lithium | 2 | 2023 | 71 | 0.540 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2023 | 3844 | 0.510 |
Why?
|
| Substance-Related Disorders | 3 | 2022 | 491 | 0.490 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 481 | 0.480 |
Why?
|
| Benzodiazepines | 2 | 2013 | 108 | 0.470 |
Why?
|
| Amygdala | 3 | 2021 | 83 | 0.430 |
Why?
|
| Humans | 55 | 2025 | 132201 | 0.400 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2025 | 855 | 0.390 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2681 | 0.360 |
Why?
|
| Adolescent | 14 | 2025 | 20557 | 0.360 |
Why?
|
| Impulsive Behavior | 3 | 2025 | 159 | 0.360 |
Why?
|
| Mood Disorders | 4 | 2025 | 129 | 0.350 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2025 | 326 | 0.330 |
Why?
|
| Neuroimaging | 5 | 2021 | 374 | 0.320 |
Why?
|
| Gray Matter | 3 | 2020 | 44 | 0.310 |
Why?
|
| Female | 32 | 2025 | 70754 | 0.300 |
Why?
|
| Child | 14 | 2023 | 25783 | 0.300 |
Why?
|
| Anhedonia | 2 | 2025 | 36 | 0.280 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 6 | 2024 | 229 | 0.280 |
Why?
|
| Adult | 23 | 2025 | 31600 | 0.280 |
Why?
|
| Marijuana Abuse | 2 | 2022 | 53 | 0.270 |
Why?
|
| White Matter | 2 | 2022 | 211 | 0.260 |
Why?
|
| Child Abuse | 2 | 2023 | 204 | 0.260 |
Why?
|
| Psychotropic Drugs | 3 | 2025 | 129 | 0.260 |
Why?
|
| Male | 26 | 2025 | 64979 | 0.250 |
Why?
|
| Organ Size | 5 | 2019 | 446 | 0.240 |
Why?
|
| Psychopharmacology | 1 | 2025 | 8 | 0.240 |
Why?
|
| Mental Disorders | 3 | 2024 | 893 | 0.230 |
Why?
|
| Irritable Mood | 1 | 2025 | 11 | 0.230 |
Why?
|
| Middle Aged | 15 | 2025 | 29007 | 0.220 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 66 | 0.220 |
Why?
|
| Putamen | 1 | 2024 | 21 | 0.220 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2024 | 33 | 0.220 |
Why?
|
| Resilience, Psychological | 1 | 2025 | 80 | 0.210 |
Why?
|
| Milk Banks | 1 | 2023 | 4 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 105 | 0.210 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2024 | 98 | 0.210 |
Why?
|
| Cyclothymic Disorder | 1 | 2023 | 3 | 0.210 |
Why?
|
| Pyrroles | 1 | 2024 | 182 | 0.200 |
Why?
|
| Stress, Psychological | 2 | 2020 | 577 | 0.190 |
Why?
|
| Brain | 4 | 2021 | 3183 | 0.190 |
Why?
|
| Trazodone | 1 | 2022 | 6 | 0.190 |
Why?
|
| Piperidines | 1 | 2024 | 235 | 0.190 |
Why?
|
| Quinolones | 2 | 2013 | 58 | 0.190 |
Why?
|
| Cognition | 3 | 2023 | 811 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 3760 | 0.190 |
Why?
|
| Suicide, Attempted | 3 | 2019 | 154 | 0.190 |
Why?
|
| Cannabis | 1 | 2022 | 49 | 0.180 |
Why?
|
| Antidepressive Agents | 5 | 2025 | 327 | 0.180 |
Why?
|
| Endophenotypes | 1 | 2021 | 13 | 0.180 |
Why?
|
| Hallucinogens | 1 | 2022 | 51 | 0.180 |
Why?
|
| Pyrimidines | 1 | 2024 | 418 | 0.180 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2023 | 128 | 0.170 |
Why?
|
| Milk, Human | 1 | 2023 | 308 | 0.170 |
Why?
|
| Piperazines | 2 | 2013 | 255 | 0.170 |
Why?
|
| Aggression | 2 | 2021 | 231 | 0.170 |
Why?
|
| Yoga | 1 | 2020 | 13 | 0.160 |
Why?
|
| Meditation | 1 | 2020 | 20 | 0.160 |
Why?
|
| Young Adult | 8 | 2025 | 9965 | 0.160 |
Why?
|
| Pituitary-Adrenal System | 1 | 2019 | 44 | 0.160 |
Why?
|
| Nucleus Accumbens | 1 | 2020 | 56 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 68 | 0.160 |
Why?
|
| Happiness | 1 | 2019 | 13 | 0.150 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2019 | 15 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2025 | 1699 | 0.150 |
Why?
|
| Atrophy | 2 | 2016 | 251 | 0.150 |
Why?
|
| Aged | 7 | 2025 | 21456 | 0.150 |
Why?
|
| Evoked Potentials | 1 | 2019 | 121 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2025 | 651 | 0.140 |
Why?
|
| Electroencephalography | 1 | 2023 | 908 | 0.140 |
Why?
|
| Fear | 1 | 2019 | 205 | 0.140 |
Why?
|
| Bayes Theorem | 1 | 2019 | 312 | 0.140 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2017 | 16 | 0.140 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 236 | 0.130 |
Why?
|
| Case-Control Studies | 6 | 2025 | 3414 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 990 | 0.130 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 316 | 0.130 |
Why?
|
| Life Change Events | 1 | 2017 | 65 | 0.130 |
Why?
|
| Psychomotor Agitation | 2 | 2014 | 57 | 0.130 |
Why?
|
| Time | 1 | 2016 | 99 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2016 | 94 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2024 | 240 | 0.120 |
Why?
|
| Italy | 3 | 2025 | 130 | 0.120 |
Why?
|
| Models, Neurological | 1 | 2017 | 215 | 0.120 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 161 | 0.110 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 25 | 0.110 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 734 | 0.100 |
Why?
|
| Memantine | 1 | 2012 | 18 | 0.100 |
Why?
|
| Histrionic Personality Disorder | 1 | 2012 | 1 | 0.090 |
Why?
|
| Factitious Disorders | 1 | 2012 | 2 | 0.090 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2012 | 6 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 98 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 3015 | 0.090 |
Why?
|
| Malformations of Cortical Development | 1 | 2012 | 54 | 0.090 |
Why?
|
| Panic Disorder | 1 | 2012 | 52 | 0.090 |
Why?
|
| Stalking | 1 | 2011 | 5 | 0.090 |
Why?
|
| Risk Factors | 2 | 2024 | 10944 | 0.090 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2012 | 50 | 0.090 |
Why?
|
| Sandfly fever Naples virus | 1 | 2010 | 2 | 0.090 |
Why?
|
| Bunyaviridae Infections | 1 | 2010 | 8 | 0.090 |
Why?
|
| Electroconvulsive Therapy | 1 | 2012 | 82 | 0.090 |
Why?
|
| Meningitis, Aseptic | 1 | 2010 | 14 | 0.090 |
Why?
|
| Encephalitis, Viral | 1 | 2010 | 21 | 0.090 |
Why?
|
| Clozapine | 1 | 2010 | 26 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 239 | 0.080 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 34 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2010 | 49 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2024 | 6569 | 0.080 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 150 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 3402 | 0.080 |
Why?
|
| Disease Progression | 1 | 2016 | 2230 | 0.080 |
Why?
|
| Personality | 1 | 2010 | 114 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2010 | 140 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 286 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1653 | 0.080 |
Why?
|
| Psychometrics | 2 | 2025 | 693 | 0.080 |
Why?
|
| Gyrus Cinguli | 2 | 2023 | 131 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1499 | 0.070 |
Why?
|
| Inpatients | 1 | 2011 | 553 | 0.060 |
Why?
|
| Cerebellum | 2 | 2023 | 462 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3995 | 0.060 |
Why?
|
| Temporal Lobe | 2 | 2019 | 118 | 0.060 |
Why?
|
| Tropanes | 1 | 2024 | 2 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17391 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2019 | 14735 | 0.050 |
Why?
|
| Anisotropy | 1 | 2022 | 122 | 0.050 |
Why?
|
| Dopamine | 1 | 2024 | 253 | 0.050 |
Why?
|
| Aripiprazole | 2 | 2013 | 22 | 0.050 |
Why?
|
| Mice | 1 | 2019 | 18504 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2022 | 104 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2023 | 233 | 0.050 |
Why?
|
| Sex Factors | 1 | 2025 | 1354 | 0.040 |
Why?
|
| Calcium Channels, L-Type | 1 | 2021 | 52 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2022 | 253 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 141 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 372 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 635 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 34842 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1444 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2023 | 13028 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 236 | 0.040 |
Why?
|
| Health | 1 | 2019 | 35 | 0.040 |
Why?
|
| Reward | 1 | 2020 | 116 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 551 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 2920 | 0.040 |
Why?
|
| Students | 1 | 2020 | 263 | 0.030 |
Why?
|
| Anticonvulsants | 2 | 2011 | 390 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 1295 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1250 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 899 | 0.030 |
Why?
|
| Self Report | 1 | 2020 | 553 | 0.030 |
Why?
|
| Rest | 1 | 2017 | 66 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2017 | 108 | 0.030 |
Why?
|
| Pregnancy | 2 | 2024 | 7557 | 0.030 |
Why?
|
| Internal Capsule | 1 | 2016 | 51 | 0.030 |
Why?
|
| Thalamus | 1 | 2016 | 88 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 1008 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5173 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1186 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1830 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 20 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2013 | 105 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 2161 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 196 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 6452 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 5410 | 0.020 |
Why?
|
| Machiavellianism | 1 | 2012 | 2 | 0.020 |
Why?
|
| Munchausen Syndrome by Proxy | 1 | 2012 | 5 | 0.020 |
Why?
|
| Septum of Brain | 1 | 2012 | 5 | 0.020 |
Why?
|
| Solid Phase Extraction | 1 | 2012 | 5 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 153 | 0.020 |
Why?
|
| Locus Coeruleus | 1 | 2012 | 21 | 0.020 |
Why?
|
| Forensic Psychiatry | 1 | 2012 | 14 | 0.020 |
Why?
|
| Muscle Relaxants, Central | 1 | 2012 | 39 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2851 | 0.020 |
Why?
|
| Prodromal Symptoms | 1 | 2012 | 10 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2012 | 77 | 0.020 |
Why?
|
| Calibration | 1 | 2012 | 99 | 0.020 |
Why?
|
| Romania | 1 | 2011 | 4 | 0.020 |
Why?
|
| Reactive Attachment Disorder | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 2011 | 21 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 74 | 0.020 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2010 | 11 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 242 | 0.020 |
Why?
|
| Gliosis | 1 | 2010 | 33 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2010 | 59 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8548 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2012 | 104 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2011 | 163 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2010 | 95 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2013 | 332 | 0.020 |
Why?
|
| Patient Admission | 1 | 2011 | 187 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2010 | 131 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2012 | 269 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 327 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1610 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2012 | 247 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 1175 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2010 | 250 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3091 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2010 | 235 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 326 | 0.020 |
Why?
|
| Personality Disorders | 1 | 2011 | 169 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13048 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1841 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1161 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 7123 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2702 | 0.010 |
Why?
|
| Hospitalization | 1 | 2013 | 1902 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 1204 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 2663 | 0.010 |
Why?
|